Navigation Links
BioLineRx Reports Third Quarter 2013 Financial Results
Date:11/13/2013

ncing activities in the 2012 period reflect the private placement completed in February 2012. The cash flows from financing activities in the 2013 period reflect the direct placement to OrbiMed completed in February 2013, as well as funding under the share purchase agreement with Lincoln Park Capital.

Conference Call and Webcast InformationBioLineRx will hold a conference call to discuss its third quarter 2013 results today, November 13, 2013, at 10:00 a.m. EST. The conference call will be available via webcast and can be accessed through the Investor Relations section of BioLineRx's website, www.biolinerx.com, and through www.kcsa.com. A presentation will be provided on BioLineRx's website to accompany management's remarks during the conference call. To dial into the conference call, please dial 1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A replay of the conference call will be available approximately two hours after completion of the live conference call at www.biolinerx.com or www.kcsa.com. A dial-in replay of the call will also be available until November 16, 2013. To access the replay, please dial 1-888-254-7270 from the U.S. or +972-3-925-5927 internationally.

(Tables follow)About BioLineRxBioLineRx is a publicly-traded biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs, as well as those with advantages over currently available therapies. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including:
'/>"/>

SOURCE BioLineRx Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
2. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
3. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
4. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
5. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
6. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
7. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
8. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
9. BioLineRx to Present at 15th International Celiac Disease Symposium
10. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
11. BioLineRx Appoints B. J. Bormann to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Actavis plc (NYSE: ACT ) ... complete response letter from the U.S. Food and ... (NDA) for the fixed-dose combination (FDC) of nebivolol ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... of a complete response letter, Actavis remains committed ...
(Date:12/24/2014)... 24, 2014  The International Trade Commission (ITC) issued its ... BMC Medical. In a notice issued on December 23, the ... patent on its humidifier was invalid. BMC President, ... "We are very excited with the ITC,s decision in this ... have taken since the very beginning on the key patents ...
(Date:12/24/2014)... Dec. 23, 2014 PuraMed BioScience®, Inc., (OTC ... (OTC) medicinal and healthcare products, announced it received the ... a hemp-based, advanced headache relief product, for planned distribution ... Colorado , Washington State ... With the MigraPure H Advanced headache relief gel formulation ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... BEND, Oregon, December 15 Bend Research Inc. announced,today that its ... used in technologies developed by the firm to enhance the oral,bioavailability ... clients may now reference a Type V Drug Master File (DMF),for ... , "We,re excited about this new development ...
... , MALVERN, Pa., Dec. 14 Fujirebio Diagnostics Inc., ... the Year by the Eastern Technology Council at a gala ... December 3, 2009. , The Eastern Technology Council ... association. Known as "The Academy Awards" of the Technology and ...
Cached Medicine Technology:Bend Research Clients May Now Reference Key Safety Document for Important Solubility Excipient 2Fujirebio Diagnostics Named Life Sciences Company of the Year 2
(Date:12/26/2014)... (PRWEB) December 26, 2014 “Many people ... with personal injury claim issues and phone calls with ... released an article featuring their free eBook on ... helpful eBook on pedestrian and bicycle auto accident claims ... is fully capable of professionally handling their case while ...
(Date:12/25/2014)... The microscopy market is estimated ... reach $5,756.0 million by 2019. Optical microscopy is ... electron microscopes product segment is expected to show ... Rising focus on nanotechnology, technological advancements, and increasing ... market. , Get Full Copy of Report @ ...
(Date:12/25/2014)... New York (PRWEB) December 25, 2014 ... 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue ... reports. According to an Order issued in the U.S. ... the Court will convene an open conference on January ... and United States Courthouse in West Palm Beach, Florida. ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Very sick children with complex chronic illnesses can receive effective, ... "medical home," with easy access to a team of dedicated ... less likely to become seriously ill and need either hospitalization ... treatment at an enhanced medical home clinic at the University ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... Watch Policy against preparing for Bird flu epidemic may be ... taking intensified precautionary measures for curbing in case of a ... India to beef up // its precautionary measures to ... threat this winter from china due to spread from migratory ...
... Virginia Commonwealth University have found that increased levels of ... responsible for increasing the risk of heart disease in ... inflammation of the supporting tissue that surrounds the teeth. ... host of diseases including diabetes and cardiovascular disease. The ...
... funded survey indicates that the ageing population in Kerala which ... a day and most are non-vegetarians. ,Almost ... in Kerala eat three meals a day, according to ‘Kerala ... some interesting problem with the health of the elderly population. ...
... facing a new threat of bird flu panic fallowing ... ministry is undergoing tests for isolating// and identification of ... were no earlier reports on isolation of the virulent ... are confident that the strain is not spread from ...
... says that squinting at your computer screens is bad for the ... to eye strain, irritation and tearing // . Researchers at the ... they put themselves at risk for dry eye. ,"People ... display, and that squinting makes the blink rate go way down," ...
... in the December 1, 2005, issue of the International ... of radiation therapy // and chemotherapy could ... ,The journal, which is the official publication ... (ASTRO), adds that this combination approach is better than ...
Cached Medicine News:Health News:Severe Gum Disease Triples Heart Disease Risk 2Health News:Three meals daily Keeps 'Kerala's elderly Healthy 2Health News:Radiation And Chemotherapy, A Better Option For Head And Neck Cancer 2
ISI Self-Supporting Arm Table offers the easy accessibility for surgeons, technicians and equipment during upper extremity surgeries....
MagPrep® Streptavidin Beads are encapsulated super-paramagnetic polystyrol particles coated with streptavidin. The beads have a diameter of 1 m and are provided as a stabilized aqueous suspensio...
BioVintages Biotin-Trapper™ Streptavidin Magnetic Beads (1 mm - 2 mm) are designed for single-step capture of biotinylated molecules such as DNA, RNA or protein from cell lysates or hybridizatio...
QuantumPlex is a bead kit for multiple analyte-detection research applications in flow cytometry. The beads may be analyzed with any standard cytometer and do not require the use of specialized softw...
Medicine Products: